Carmen Gutiérrez-Muñoz, Rafael Blázquez-Serra, Irene San Sebastian-Jaraba, Sandra Sanz-Andrea, Maria J. Fernández-Gómez, Gonzalo Nuñez-Moreno, Pablo Mínguez, Joan Carles Escolá-Gil, Paula Nogales, Veronique Ollivier, Jose L. Martín-Ventura, Benoit Ho-Tin Noe, Ursula Rescher, Nerea Méndez-Barbero, Luis M. Blanco-Colio
{"title":"膜联蛋白A8缺乏可延缓动脉粥样硬化进展。","authors":"Carmen Gutiérrez-Muñoz, Rafael Blázquez-Serra, Irene San Sebastian-Jaraba, Sandra Sanz-Andrea, Maria J. Fernández-Gómez, Gonzalo Nuñez-Moreno, Pablo Mínguez, Joan Carles Escolá-Gil, Paula Nogales, Veronique Ollivier, Jose L. Martín-Ventura, Benoit Ho-Tin Noe, Ursula Rescher, Nerea Méndez-Barbero, Luis M. Blanco-Colio","doi":"10.1002/ctm2.70176","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall. By studying the aortic transcriptome of atherosclerosis-prone apolipoprotein E (<i>ApoE<sup>−/−</sup>)</i> mice, we aimed to identify novel players in the progression of atherosclerosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>RNA-Seq analysis was performed on aortas from <i>ApoE<sup>−/−</sup></i> and wild-type mice. AnxA8 expression was assessed in human and mice atherosclerotic tissue and healthy aorta. <i>ApoE<sup>−/−</sup></i> mice lacking systemic AnxA8 (<i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i>) were generated to assess the effect of AnxA8 deficiency on atherosclerosis. Bone marrow transplantation (BMT) was also performed to generate <i>ApoE<sup>−/−</sup></i> lacking AnxA8 specifically in bone marrow-derived cells. Endothelial-specific AnxA8 silencing in vivo was performed in <i>ApoE<sup>−/−</sup></i> mice. The functional role of AnxA8 was analysed in cultured murine cells.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>RNA-Seq unveiled <i>AnxA8</i> as one of the most significantly upregulated genes in atherosclerotic aortas of <i>ApoE<sup>−/−</sup></i> compared to wild-type mice. Moreover, AnxA8 was upregulated in human atherosclerotic plaques. Germline deletion of AnxA8 decreased the atherosclerotic burden, the size and volume of atherosclerotic plaques in the aortic root. Plaques of <i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i> were characterized by lower lipid and inflammatory content, smaller necrotic core, thicker fibrous cap and less apoptosis compared with those in <i>ApoE<sup>−/−</sup>AnxA8<sup>+/+</sup></i>. BMT showed that hematopoietic AnxA8 deficiency had no effect on atherosclerotic progression. Oxidized low-density lipoprotein (ox-LDL) increased AnxA8 expression in murine aortic endothelial cells (MAECs). In vitro experiments revealed that <i>AnxA8</i> deficiency in MAECs suppressed P/E-selectin and CD31 expression and secretion induced by ox-LDL with a concomitant reduction in platelet and leukocyte adhesion. Intravital microscopy confirmed the reduction in leukocyte and platelet adhesion in <i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i> mice. Finally, endothelial-specific silencing of AnxA8 decreased atherosclerosis progression.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our findings demonstrate that AnxA8 promotes the progression of atherosclerosis by modulating endothelial−leukocyte interactions. Interventions capable of reducing AnxA8 expression in endothelial cells may delay atherosclerotic plaque progression.</p>\n </section>\n \n <section>\n \n <h3> Key points</h3>\n \n <div>\n <ul>\n \n <li>\n <p>This study shows that AnxA8 is upregulated in aorta of atheroprone mice and in human atherosclerotic plaques.</p>\n </li>\n \n <li>\n <p>Germline AnxA8 deficiency reduces platelet and leukocyte recruitment to activated endothelium as well as atherosclerotic burden, plaque size, and macrophage accumulation in mice.</p>\n </li>\n \n <li>\n <p>AnxA8 regulates oxLDL-induced adhesion molecules expression in aortic endothelial cells. Our data strongly suggest that AnxA8 promotes disease progression through regulation of adhesion and influx of immune cells to the intima.</p>\n </li>\n \n <li>\n <p>Endothelial specific silencing of AnxA8 reduced atherosclerosis progression.</p>\n </li>\n \n <li>\n <p>Therapeutic interventions to reduce AnxA8 expression may delay atherosclerosis progression.</p>\n </li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"15 1","pages":""},"PeriodicalIF":7.9000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748212/pdf/","citationCount":"0","resultStr":"{\"title\":\"Annexin A8 deficiency delays atherosclerosis progression\",\"authors\":\"Carmen Gutiérrez-Muñoz, Rafael Blázquez-Serra, Irene San Sebastian-Jaraba, Sandra Sanz-Andrea, Maria J. Fernández-Gómez, Gonzalo Nuñez-Moreno, Pablo Mínguez, Joan Carles Escolá-Gil, Paula Nogales, Veronique Ollivier, Jose L. Martín-Ventura, Benoit Ho-Tin Noe, Ursula Rescher, Nerea Méndez-Barbero, Luis M. Blanco-Colio\",\"doi\":\"10.1002/ctm2.70176\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall. By studying the aortic transcriptome of atherosclerosis-prone apolipoprotein E (<i>ApoE<sup>−/−</sup>)</i> mice, we aimed to identify novel players in the progression of atherosclerosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>RNA-Seq analysis was performed on aortas from <i>ApoE<sup>−/−</sup></i> and wild-type mice. AnxA8 expression was assessed in human and mice atherosclerotic tissue and healthy aorta. <i>ApoE<sup>−/−</sup></i> mice lacking systemic AnxA8 (<i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i>) were generated to assess the effect of AnxA8 deficiency on atherosclerosis. Bone marrow transplantation (BMT) was also performed to generate <i>ApoE<sup>−/−</sup></i> lacking AnxA8 specifically in bone marrow-derived cells. Endothelial-specific AnxA8 silencing in vivo was performed in <i>ApoE<sup>−/−</sup></i> mice. The functional role of AnxA8 was analysed in cultured murine cells.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>RNA-Seq unveiled <i>AnxA8</i> as one of the most significantly upregulated genes in atherosclerotic aortas of <i>ApoE<sup>−/−</sup></i> compared to wild-type mice. Moreover, AnxA8 was upregulated in human atherosclerotic plaques. Germline deletion of AnxA8 decreased the atherosclerotic burden, the size and volume of atherosclerotic plaques in the aortic root. Plaques of <i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i> were characterized by lower lipid and inflammatory content, smaller necrotic core, thicker fibrous cap and less apoptosis compared with those in <i>ApoE<sup>−/−</sup>AnxA8<sup>+/+</sup></i>. BMT showed that hematopoietic AnxA8 deficiency had no effect on atherosclerotic progression. Oxidized low-density lipoprotein (ox-LDL) increased AnxA8 expression in murine aortic endothelial cells (MAECs). In vitro experiments revealed that <i>AnxA8</i> deficiency in MAECs suppressed P/E-selectin and CD31 expression and secretion induced by ox-LDL with a concomitant reduction in platelet and leukocyte adhesion. Intravital microscopy confirmed the reduction in leukocyte and platelet adhesion in <i>ApoE<sup>−/−</sup>AnxA8<sup>−/−</sup></i> mice. Finally, endothelial-specific silencing of AnxA8 decreased atherosclerosis progression.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Our findings demonstrate that AnxA8 promotes the progression of atherosclerosis by modulating endothelial−leukocyte interactions. Interventions capable of reducing AnxA8 expression in endothelial cells may delay atherosclerotic plaque progression.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Key points</h3>\\n \\n <div>\\n <ul>\\n \\n <li>\\n <p>This study shows that AnxA8 is upregulated in aorta of atheroprone mice and in human atherosclerotic plaques.</p>\\n </li>\\n \\n <li>\\n <p>Germline AnxA8 deficiency reduces platelet and leukocyte recruitment to activated endothelium as well as atherosclerotic burden, plaque size, and macrophage accumulation in mice.</p>\\n </li>\\n \\n <li>\\n <p>AnxA8 regulates oxLDL-induced adhesion molecules expression in aortic endothelial cells. Our data strongly suggest that AnxA8 promotes disease progression through regulation of adhesion and influx of immune cells to the intima.</p>\\n </li>\\n \\n <li>\\n <p>Endothelial specific silencing of AnxA8 reduced atherosclerosis progression.</p>\\n </li>\\n \\n <li>\\n <p>Therapeutic interventions to reduce AnxA8 expression may delay atherosclerosis progression.</p>\\n </li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":10189,\"journal\":{\"name\":\"Clinical and Translational Medicine\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":7.9000,\"publicationDate\":\"2025-01-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748212/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70176\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70176","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:动脉粥样硬化是一种以动脉壁内脂质和白细胞积聚为特征的慢性炎症性疾病。通过研究动脉粥样硬化易感性载脂蛋白E (ApoE-/-)小鼠的主动脉转录组,我们旨在确定动脉粥样硬化进展中的新参与者。方法:对ApoE-/-和野生型小鼠的主动脉进行RNA-Seq分析。在人和小鼠动脉粥样硬化组织和健康主动脉中检测AnxA8的表达。产生ApoE-/-系统性缺乏AnxA8的小鼠(ApoE-/-AnxA8-/-),以评估AnxA8缺乏对动脉粥样硬化的影响。骨髓移植(BMT)也可以在骨髓源性细胞中产生特异性缺乏ApoE-/-的AnxA8。在ApoE-/-小鼠体内进行内皮特异性AnxA8沉默。在小鼠培养细胞中分析了AnxA8的功能作用。结果:RNA-Seq显示,与野生型小鼠相比,ApoE-/-小鼠动脉粥样硬化主动脉中,AnxA8是表达上调最显著的基因之一。此外,AnxA8在人类动脉粥样硬化斑块中表达上调。种系缺失AnxA8可降低动脉粥样硬化负荷、主动脉根部动脉粥样硬化斑块的大小和体积。与ApoE-/- anxa8 +/+相比,ApoE-/- anxa8 -/-斑块的特点是脂质和炎症含量较低,坏死核心较小,纤维帽较厚,细胞凋亡较少。BMT显示造血AnxA8缺乏对动脉粥样硬化的进展没有影响。氧化低密度脂蛋白(ox-LDL)增加小鼠主动脉内皮细胞(MAECs)中AnxA8的表达。体外实验表明,MAECs中AnxA8缺乏可抑制ox-LDL诱导的P/ e -选择素和CD31的表达和分泌,同时血小板和白细胞粘附减少。活体显微镜证实ApoE-/- anxa8 -/-小鼠白细胞和血小板粘附减少。最后,内皮特异性沉默AnxA8可减少动脉粥样硬化的进展。结论:我们的研究结果表明,AnxA8通过调节内皮-白细胞相互作用促进动脉粥样硬化的进展。能够降低内皮细胞中AnxA8表达的干预措施可能会延缓动脉粥样硬化斑块的进展。本研究表明,AnxA8在动脉粥样硬化小鼠主动脉和人类动脉粥样硬化斑块中表达上调。种系AnxA8缺乏可减少小鼠血小板和白细胞向活化内皮的募集,以及动脉粥样硬化负荷、斑块大小和巨噬细胞积聚。AnxA8调控氧化低密度脂蛋白诱导的主动脉内皮细胞粘附分子的表达。我们的数据强烈表明,AnxA8通过调节免疫细胞对内膜的粘附和内流来促进疾病进展。内皮特异性沉默AnxA8可减少动脉粥样硬化进展。降低AnxA8表达的治疗干预可能会延缓动脉粥样硬化的进展。
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and leukocytes within the arterial wall. By studying the aortic transcriptome of atherosclerosis-prone apolipoprotein E (ApoE−/−) mice, we aimed to identify novel players in the progression of atherosclerosis.
Methods
RNA-Seq analysis was performed on aortas from ApoE−/− and wild-type mice. AnxA8 expression was assessed in human and mice atherosclerotic tissue and healthy aorta. ApoE−/− mice lacking systemic AnxA8 (ApoE−/−AnxA8−/−) were generated to assess the effect of AnxA8 deficiency on atherosclerosis. Bone marrow transplantation (BMT) was also performed to generate ApoE−/− lacking AnxA8 specifically in bone marrow-derived cells. Endothelial-specific AnxA8 silencing in vivo was performed in ApoE−/− mice. The functional role of AnxA8 was analysed in cultured murine cells.
Results
RNA-Seq unveiled AnxA8 as one of the most significantly upregulated genes in atherosclerotic aortas of ApoE−/− compared to wild-type mice. Moreover, AnxA8 was upregulated in human atherosclerotic plaques. Germline deletion of AnxA8 decreased the atherosclerotic burden, the size and volume of atherosclerotic plaques in the aortic root. Plaques of ApoE−/−AnxA8−/− were characterized by lower lipid and inflammatory content, smaller necrotic core, thicker fibrous cap and less apoptosis compared with those in ApoE−/−AnxA8+/+. BMT showed that hematopoietic AnxA8 deficiency had no effect on atherosclerotic progression. Oxidized low-density lipoprotein (ox-LDL) increased AnxA8 expression in murine aortic endothelial cells (MAECs). In vitro experiments revealed that AnxA8 deficiency in MAECs suppressed P/E-selectin and CD31 expression and secretion induced by ox-LDL with a concomitant reduction in platelet and leukocyte adhesion. Intravital microscopy confirmed the reduction in leukocyte and platelet adhesion in ApoE−/−AnxA8−/− mice. Finally, endothelial-specific silencing of AnxA8 decreased atherosclerosis progression.
Conclusion
Our findings demonstrate that AnxA8 promotes the progression of atherosclerosis by modulating endothelial−leukocyte interactions. Interventions capable of reducing AnxA8 expression in endothelial cells may delay atherosclerotic plaque progression.
Key points
This study shows that AnxA8 is upregulated in aorta of atheroprone mice and in human atherosclerotic plaques.
Germline AnxA8 deficiency reduces platelet and leukocyte recruitment to activated endothelium as well as atherosclerotic burden, plaque size, and macrophage accumulation in mice.
AnxA8 regulates oxLDL-induced adhesion molecules expression in aortic endothelial cells. Our data strongly suggest that AnxA8 promotes disease progression through regulation of adhesion and influx of immune cells to the intima.
Endothelial specific silencing of AnxA8 reduced atherosclerosis progression.
Therapeutic interventions to reduce AnxA8 expression may delay atherosclerosis progression.
期刊介绍:
Clinical and Translational Medicine (CTM) is an international, peer-reviewed, open-access journal dedicated to accelerating the translation of preclinical research into clinical applications and fostering communication between basic and clinical scientists. It highlights the clinical potential and application of various fields including biotechnologies, biomaterials, bioengineering, biomarkers, molecular medicine, omics science, bioinformatics, immunology, molecular imaging, drug discovery, regulation, and health policy. With a focus on the bench-to-bedside approach, CTM prioritizes studies and clinical observations that generate hypotheses relevant to patients and diseases, guiding investigations in cellular and molecular medicine. The journal encourages submissions from clinicians, researchers, policymakers, and industry professionals.